Phase 2 Failures

Woman seated at a desk, monitoring four computer monitors displaying data dashboards and flowcharts in a dim blue-lit office.

Enpatoran’s Phase 2 Miss Exposes a Protocol Design Flaw That Every SLE Sponsor Needs to Confront

Enpatoran improved BICLA response rates in moderate-to-severe SLE but failed its primary dose-dependent endpoint—a design flaw sponsors can't afford...

By Moe Alsumidaie
May 9, 2026

Moe Alsumidaie

Chief Editor

Phase 2 Failures

Enpatoran’s Phase 2 Miss Exposes a Protocol Design Flaw That Every SLE Sponsor Needs to Confront